Anti-Mouse CD122/IL-2Rβ Antibody (5H4)
Based on 1 Customer Validation
Anti-Mouse CD122/IL-2Rβ Antibody (5H4) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD122/IL-2Rβ. Anti-Mouse CD122/IL-2Rβ Antibody (5H4) can inhibit IL-2. Anti-Mouse CD122/IL-2Rβ Antibody (5H4) can be used for the researches of cancer and immunology, such as hepatocellular carcinoma.
For research use only. We do not sell to patients.
- Purity : ≥95.0%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Rat IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
CD122/IL-2Rβ
In Vitro
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse CD122/IL-2Rβ Antibody (5H4) (100 μg/mouse, i.p., at days 7, 9, 12, 14 and 16) reduces CD8+CD122+ T cell population in B6 mice[2].
Anti-Mouse CD122/IL-2Rβ Antibody (5H4) (100 μg/mouse, i.p., every 2-3 days for 5 times) suppresses tumor growth and prolongs survival companied with tumor vaccine in B16-OVA tumor mice models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B16-OVA tumor mice models[1]
-
Dosage:100 μg/mouse, companied with tumor vaccine
-
Administration:Intraperitoneally injection, every 2-3 days for 5 times
-
Result:Inhibited tumor growth with 10% long-term survival.
Reduced the frequency of G-MDSCs.
Increased the dual IFNγ/TNFα production from effector CD8+ TILs.
Enhanced the OVA-tetramer-specific CD8+CD44+ memory T cells in the tumors.
Reduced the frequency of CD4+ Tregs.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vitro NK cell negative selection; Immunoprecipitation; Flow cytometry
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD122/IL-2Rβ Antibody (5H4)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Lacotte S, et al. Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth. Oncoimmunology. 2023 Mar 2;12(1):2184991. [Content Brief]
[2]. Villarreal DO, et al. Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment. Oncotarget. 2017 Nov 24;8(65):109151-109160. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)